替吉奥联合伊立替康治疗晚期结直肠癌的临床疗效观察  

Clinical Effect Observation of S-1 Combined with Irinotecan for Patients with Advanced Colorectal Carcinoma

作　　者：高亚丽[1] 韩英民[1] 侯建峰[1] 

机构地区：[1]郑州大学附属洛阳中心医院,河南洛阳471009

出　　处：《中国医学创新》2013年第16期17-19,共3页Medical Innovation of China

摘　　要：目的:探讨替吉奥联合伊立替康在结直肠癌化疗中的疗效及安全性。方法:将64例结直肠癌患者随机分为两组,研究组31例,使用替吉奥联合伊立替康,对照组33例,采用FOLFIRI方案。结果:入组病例均可进行疗效评价。研究组完全缓解率(CR)12.9%,部分缓解率(PR)51.6%,有效率(RR)64.5%,对照组完全缓解率(CR)6.1%,部分缓解率(PR)39.4%,有效率(RR)45.5%。研究组有效率高于对照组,但差异无统计学意义(P>0.05)。不良反应:两组白细胞减少、腹泻、恶心呕吐、肝功能异常方面差异有统计学意义(P<0.05),而在贫血、血小板减少、肾功能异常、口腔炎、周围神经损伤、手足综合征方面,两组比较差异无统计学意义(P>0.05)。研究组及对照组中位无进展期为6.6个月、4.3个月,两组比较差异有统计学意义(P<0.05)。结论:替吉奥联合伊立替康治疗结直肠癌疗效肯定,不良反应少,耐受性好。Objective： To investigate the efficacy and safety of S-1 combined with irinotecan for patients with advanced colorectal carcinoma. Method： 64 patients with advanced colorectal cancer were randomly divided into two groups.The treatment group was administrated with S-1 combined irinotecan; The control group was administrated with program FOLFIRI.Result： The effective rate was 64.5%, with 4 cases （ 12.9% ） CR, 51.6% PR, 83.9% DCR in thetreatment group , and The effective rate was 45.5%, with 2 cases （ 6.1% ） CR, 39.4% PR, DCR 72.7% in control group.Adverse reaction： leucopenia, diarrhea, nausea and vomiting, liver function abnormal aspects, significant difference was statistically significant （ P〈0.05 ）, but in anemia, thrombocytopenia, and renal abnormalities, stomatitis, peripheral nerve injury, brothers syndrome, there was no significant difference between the two groups meaning （ P〉0.05 ） .The treatment group and control group in which the median progression-free period was 6.6 months and 4.3 months, two groups of comparisons difference had statistical significance （ P〈0.05 ） .Conclusion： S-1 combined rinotecan in the treatment of advanced colorectal cancer is effective and has mild side effects.It＇s tolerance is well.

关 键 词：替吉奥 依立替康 晚期结直肠癌 

分 类 号：R735.3[医药卫生—肿瘤]